IRIS
ARMENI, PATRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.013
NA - Nord America 3.273
AS - Asia 1.678
SA - Sud America 182
AF - Africa 16
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 10
Totale 11.184
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.088
IT - Italia 2.772
GB - Regno Unito 799
IE - Irlanda 718
SG - Singapore 453
CN - Cina 434
UA - Ucraina 345
DE - Germania 318
RU - Federazione Russa 201
HK - Hong Kong 198
CA - Canada 163
SE - Svezia 162
BR - Brasile 157
TR - Turchia 149
FR - Francia 148
FI - Finlandia 141
VN - Vietnam 115
NL - Olanda 112
KR - Corea 76
IN - India 67
CZ - Repubblica Ceca 59
BG - Bulgaria 49
IL - Israele 42
BE - Belgio 40
ID - Indonesia 40
ES - Italia 28
AT - Austria 24
PL - Polonia 20
CH - Svizzera 18
RO - Romania 13
DK - Danimarca 12
IR - Iran 10
JP - Giappone 9
PH - Filippine 9
CL - Cile 8
EU - Europa 8
MX - Messico 8
TW - Taiwan 8
AU - Australia 7
AE - Emirati Arabi Uniti 6
TH - Thailandia 6
BD - Bangladesh 5
IQ - Iraq 5
JO - Giordania 5
LV - Lettonia 5
NZ - Nuova Zelanda 5
SA - Arabia Saudita 5
ZA - Sudafrica 5
AR - Argentina 4
AZ - Azerbaigian 4
CO - Colombia 4
CR - Costa Rica 4
EC - Ecuador 4
GE - Georgia 4
GR - Grecia 4
KG - Kirghizistan 4
MA - Marocco 4
MY - Malesia 4
PA - Panama 4
PK - Pakistan 4
PT - Portogallo 4
SI - Slovenia 4
LA - Repubblica Popolare Democratica del Laos 3
LT - Lituania 3
NO - Norvegia 3
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
BZ - Belize 2
EE - Estonia 2
EG - Egitto 2
HU - Ungheria 2
KZ - Kazakistan 2
LK - Sri Lanka 2
PE - Perù 2
PS - Palestinian Territory 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
BB - Barbados 1
BO - Bolivia 1
BT - Bhutan 1
DZ - Algeria 1
HN - Honduras 1
JM - Giamaica 1
KE - Kenya 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SM - San Marino 1
SV - El Salvador 1
TM - Turkmenistan 1
TN - Tunisia 1
UG - Uganda 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 11.184
Salva come PNG Salva come JPEG
Città #
Dublin 717
Milan 592
Southend 532
Chandler 484
Singapore 284
Jacksonville 276
Ann Arbor 234
Rome 231
Hong Kong 197
Toronto 138
Dearborn 128
The Dalles 118
Dong Ket 104
Beijing 101
New York 100
Houston 94
Helsinki 91
Wilmington 80
Seoul 75
Boston 71
Ashburn 69
Modena 68
Lawrence 64
Boardman 63
Munich 58
Izmir 56
Los Angeles 53
Naples 52
Moscow 46
Redwood City 41
Bari 40
Bologna 40
Redmond 39
Tel Aviv 39
Brussels 38
Jakarta 38
Florence 36
Mountain View 34
Turin 33
Woodbridge 33
Assago 32
Seattle 31
Casorate Primo 30
Frankfurt am Main 30
Catania 28
Genoa 23
Falkenstein 22
Hefei 20
Dallas 19
London 19
Amsterdam 18
Brno 18
Duncan 18
Kunming 18
Nanjing 18
São Paulo 16
Busto Arsizio 13
Cagliari 13
Palombara Sabina 13
Parma 13
Torino 13
Warsaw 13
Washington 13
Bonndorf 12
Kocaeli 12
Pisa 12
Boydton 11
Brescia 11
Paris 11
Verona 11
Fairfield 10
Melendugno 10
Palermo 10
Santa Clara 10
Vienna 10
Brooklyn 9
Düsseldorf 9
Fremont 9
Guangzhou 9
Jinan 9
Ottawa 9
Padova 9
Udine 9
Lappeenranta 8
Monza 8
Pescara 8
Prague 8
Ravenna 8
Taranto 8
Tokyo 8
Bucharest 7
Isernhagen-Süd 7
Reggio Emilia 7
Shanghai 7
Ancona 6
Berlin 6
Caserta 6
Casoria 6
Chicago 6
Council Bluffs 6
Totale 6.360
Salva come PNG Salva come JPEG
Nome #
Digitalizzazione nelle tecnologie per la salute: impatto sui livelli di governo del SSN 526
The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study 399
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 326
Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci 321
La spesa sanitaria: composizione ed evoluzione 285
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 274
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 263
I dispositivi medici in Italia: un settore, tanti mercati 238
Report n. 42 OSFAR (Osservatorio Farmaci) 211
L'acquisto di farmaci in Italia: l'effetto di approcci selettivi 189
Programma Nazionale di HTA per dispositivi medici: prove tecniche di implementazione 187
Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento 184
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 184
Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa 181
La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane 180
PHP3 the simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 180
Il confronto dei sistemi sanitari in una prospettiva internazionale 172
Market access management by pharmaceutical companies in a complex environment: the Italian case study 172
Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation 167
The future of Funds for Innovative Medicines: results from a Delphi Study 161
A value-based revolution in health care: perspectives, challenges, and emerging approaches to defining and measuring the value of health care technologies 160
The impact of HTA and procurement practices on the selection and prices of medical devices 158
Diffusion without evidence: a study on high-risk medical devices 157
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 155
Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis 154
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service 152
Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review 145
L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni 144
The impact of generic reference pricing in Italy, a decade on 142
A meta-analysis of MitraClip combined with medical therapy versus medical therapy alone for treatment of mitral regurgitation in heart failure patients 141
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) 141
La spesa sanitaria: composizione ed evoluzione 140
The impact of generic reference pricing in Italy, a decade on 138
Il confronto dei sistemi sanitari in una prospettiva internazionale 136
La spesa sanitaria: composizione ed evoluzione 134
When peers count: the effects on integrated type II diabetes care of communication within general practitioner-only subgroups in interprofessional primary care teams 133
Il confronto dei sistemi sanitari in una prospettiva internazionale 132
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy 125
Cost-benefit analysis in health care: the case of bariatric surgery compared with diet 124
The social burden and quality of life of patients with haemophilia in Italy 123
L'attività sperimentale sui dispositivi medici 122
Social/economic costs and quality of life in patients with haemophilia in Europe 121
Multi-professional primary care units: what affects the clinical performance of Italian general practitioners? 120
The invisible costs of obstructive sleep apnea (OSA): systematic review and cost-of-illness analysis 118
Il confronto dei sistemi sanitari in una prospettiva internazionale 118
Digital Twins in healthcare: is it the beginning of a new era of evidence-based medicine? A critical review 117
Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey 117
I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia 115
La spesa sanitaria: composizione ed evoluzione 112
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 110
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 109
Cost-effectiveness and net monetary benefit of Olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service 109
What type of clinical evidence is needed to assess medical devices? 108
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe 107
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 106
Il confronto dei sistemi sanitari in una prospettiva internazionale 104
Implementation of value-based pricing for medicines 104
Social economic costs, health-related quality of life and disability in patients with Cri Du Chat syndrome 103
La spesa sanitaria: composizione ed evoluzione 101
The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study 97
Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients 97
Collecting physicians' preferences on medical devices: are we doing it right? Evidence from Italian orthopedists using 2 different stated preference methods 86
La spesa sanitaria: composizione ed evoluzione 85
La spesa sanitaria: composizione ed evoluzione 84
La spesa sanitaria: composizione ed evoluzione 79
La spesa sanitaria: composizione ed evoluzione 78
Variations in non-prescription drug consumption and expenditure: determinants and policy implications 78
La spesa sanitaria: composizione ed evoluzione 77
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 74
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case 70
Politiche del farmaco: approfondimento sul Value Framework per i farmaci 70
La spesa sanitaria: composizione ed evoluzione 68
Economic impact of a more extensive use of FENO testing on the Italian population with asthma 59
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention 59
The value of hearing aids for the Italian NHS: a cost-utility analysis 59
La copertura vaccinale nelle regioni italiane. Un’analisi dell’eterogeneità 58
Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure 55
Reflections on the importance of cost of illness analysis in rare diseases: a proposal 49
Use of resource modeling to quantify the organizational impact of subcutaneous formulations for the treatment of oncologic patients: the case of daratumumab in multiple myeloma 45
Cost-effectiveness analysis of HRD testing for previously treated patients with advanced ovarian cancer in Italy 40
Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe 36
Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries 36
Individual and team performanc: issues around the role of attributes and relationships among peers 33
L’evoluzione del finanziamento dei farmaci in Italia 29
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment 27
Exploring the potential of digital therapeutics: an assessment of progress and promise 13
Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy 13
The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States 12
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes 10
Totale 11.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.403
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.403
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.206 63 88 41 116 121 81 105 60 132 103 108 188
2021/2022935 68 180 36 41 66 12 31 174 41 47 105 134
2022/20232.347 119 127 58 176 153 189 63 101 977 94 165 125
2023/20241.807 104 97 123 89 167 177 105 279 99 136 211 220
2024/20252.490 138 36 170 123 209 157 162 165 571 286 303 170
2025/2026138 138 0 0 0 0 0 0 0 0 0 0 0
Totale 11.431